Open AccessCD4 cell eligibility thresholds: an analysis of the time to antiretroviral treatment in HIV-1 seroconverters
Author(s) -
Albert Minga,
Charlotte Lewden,
Delphine Gabillard,
Germain I Bomisso,
Thomas-dʼAquin Toni,
Arlette Emième,
Vincent Yapo,
André Inwoley,
Roger Salamon,
Xavier Anglaret
Publication year - 2011
Publication title -
aids
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.195
H-Index - 216
eISSN - 1473-5571
pISSN - 0269-9370
DOI - 10.1097/qad.0b013e32834625d3
Subject(s) - seroconversion , cohort , medicine , human immunodeficiency virus (hiv) , antiretroviral therapy , immunology , cohort study , antiretroviral treatment , virology , demography , viral load , sociology
WHO recommends initiating combination antiretroviral treatment at the minimal CD4 cell threshold of 350 cells/μl. In sub-Saharan Africa, the time for a recently infected patient to reach this threshold is unclear.